FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281296355> ?p ?o ?g. }

• W4281296355 abstract "Summary Background Effectiveness of oral antivirals in mild-to-moderate COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the clinical and virologic outcomes associated with molnupiravir and nirmatrelvir/ritonavir use in COVID-19 patients during a pandemic wave dominated by the Omicron BA.2 subvariant. Methods We analyzed data from a territory-wide retrospective cohort of hospitalized patients with confirmed diagnosis of SARS-CoV-2 infection from 26th February 2022 to 26th April 2022 in Hong Kong. Oral antiviral users were matched with controls using propensity-score matching in a ratio of 1:1. Study outcomes were all-cause mortality, a composite outcome of disease progression (all-cause mortality, initiation of invasive mechanical ventilation [IMV], intensive care unit admission, or the need for oxygen therapy) and their individual outcomes, and time to achieving lower viral burden of cycle threshold (Ct) value ≥30 cycles. Hazard ratios (HR) of event outcomes were estimated using Cox regression models. Results Among 40,776 hospitalized patients with SARS-CoV-2 infection over a mean follow-up of 41.3 days with 925,713 person-days, this study included 1,856 molnupiravir users, 890 nirmatrelvir/ritonavir users and 2,746 control patients not initially requiring oxygen therapy at baseline after propensity-score matching. Oral antiviral use was associated with significantly lower risks of all-cause mortality (molnupiravir: HR=0.48, 95%CI=0.40-0.59, p<0.0001; nirmatrelvir/ritonavir: HR=0.34, 95%CI=0.23-0.50, p<0.0001), the composite outcome of disease progression (molnupiravir: HR=0.60, 95%CI=0.52-0.69, p<0.0001; nirmatrelvir/ritonavir: HR=0.57, 95%CI=0.45-0.72, p<0.0001), and the need for oxygen therapy (molnupiravir: HR=0.69, 95%CI=0.57-0.83, p=0.00011; nirmatrelvir/ritonavir: HR=0.73, 95%CI=0.54-0.97, p=0.032) than non-use. Time to achieving lower viral burden was significantly shorter among oral antiviral users than matched controls (molnupiravir: HR=1.38, 95%CI=1.15-1.64, p=0.0046; nirmatrelvir/ritonavir: HR=1.38, 95%CI=1.07-1.78, p=0.013). Conclusions Against Omicron BA.2, initiation of novel oral antiviral treatment in hospitalized patients not requiring any oxygen therapy was associated with lower risks of all-cause mortality and disease progression, in addition to achieving low viral burden faster. Our findings support the early use of oral antivirals in COVID-19 patients who do not require supplemental oxygen on admission. Funding Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong SAR Research in context Evidence before this study The medical and research community are actively exploring the use of oral antivirals in COVID-19 patients to lower their risks of hospitalization and death, and to reduce the burden on healthcare systems. We searched Scopus and PubMed for studies until 13th May 2022 using the search terms “SARS-CoV-2 OR COVID-19” AND “molnupiravir OR Lagevrio OR EIDD-2801” OR “nirmatrelvir OR Paxlovid OR PF-07321332”. Major studies examining the safety and efficacy of molnupiravir include MOVe-IN and MOVe-OUT trials conducted in hospitalized and non-hospitalized COVID-19 patients, respectively. Clinical evidence for the use of ritonavir-boosted nirmatrelvir came from the EPIC-HR trial conducted among non-hospitalized adults with COVID-19. While no clinical benefits have been observed with molnupiravir use in the inpatient setting among patients with moderate-to-severe COVID-19, early initiation of molnupiravir or nirmatrelvir/ritonavir within 5 days of symptom onset in non-hospitalized patients with mild-to-moderate COVID-19 and risk factors for progression to severe disease has been associated with relative risk reduction of hospitalization or death by 30% and 88%, respectively. Notably, these clinical trials were conducted prior to the prevalence of Omicron variant, and the efficacy of oral antivirals against this current variant of concern can only be inferred from experimental evidence to date. Real-world evidence of oral antiviral use in patients with SARS-CoV-2 infection of Omicron variant is lacking. Added value of this study To the best of our knowledge, this is the first real-world study exploring the inpatient use of oral antivirals during a pandemic wave dominated by SARS-CoV-2 Omicron variant. We conducted a territory-wide, retrospective cohort study to examine the effectiveness of molnupiravir and nirmatrelvir/ritonavir in COVID-19 patients who did not require supplemental oxygen on admission in Hong Kong. Early initiation of oral antivirals within 2 days of admission was associated with significantly lower risks of all-cause mortality and disease progression, in addition to achieving low viral burden faster than their respective matched controls. Oral antiviral use was also associated with a reduced need for oxygen therapy than non-use. Implications of all the available evidence Current guidelines are now prioritizing the distribution of oral antivirals to those who do not require supplemental oxygen, but who are at the highest risk of disease progression. Our study cohort reflected such prescription pattern in real-world clinical practice, consisting of mostly the elderly with multiple pre-existing comorbidities and who had not been fully vaccinated. The antiviral effect and mortality benefit observed in this patient cohort support the use of oral antivirals in COVID-19 patients who do not require supplemental oxygen on admission during a pandemic wave of Omicron variant. Ongoing research will inform the safety and effectiveness of oral antivirals in specific patient populations (by vaccination status and viral variants), drug combinations, and different healthcare settings." @default.
• W4281296355 created "2022-05-24" @default.
• W4281296355 creator A5022209651 @default.
• W4281296355 creator A5039317388 @default.
• W4281296355 creator A5041610413 @default.
• W4281296355 creator A5045925648 @default.
• W4281296355 creator A5068660339 @default.
• W4281296355 creator A5074151633 @default.
• W4281296355 date "2022-05-20" @default.
• W4281296355 modified "2023-10-14" @default.
• W4281296355 title "Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study" @default.
• W4281296355 cites W2016403661 @default.
• W4281296355 cites W2134843796 @default.
• W4281296355 cites W2509191638 @default.
• W4281296355 cites W3094209984 @default.
• W4281296355 cites W3118685355 @default.
• W4281296355 cites W3129068943 @default.
• W4281296355 cites W3131223925 @default.
• W4281296355 cites W3157786842 @default.
• W4281296355 cites W3182515684 @default.
• W4281296355 cites W3217268039 @default.
• W4281296355 cites W4200051875 @default.
• W4281296355 cites W4200560336 @default.
• W4281296355 cites W4205092652 @default.
• W4281296355 cites W4206902820 @default.
• W4281296355 cites W4206993475 @default.
• W4281296355 cites W4211257859 @default.
• W4281296355 cites W4212949239 @default.
• W4281296355 cites W4214845310 @default.
• W4281296355 cites W4214892418 @default.
• W4281296355 cites W4220742842 @default.
• W4281296355 cites W4221081069 @default.
• W4281296355 cites W4221117156 @default.
• W4281296355 cites W4225553089 @default.
• W4281296355 cites W4226023710 @default.
• W4281296355 cites W4226164088 @default.
• W4281296355 cites W4226174287 @default.
• W4281296355 cites W4226236384 @default.
• W4281296355 cites W4226343483 @default.
• W4281296355 cites W4228997747 @default.
• W4281296355 cites W4281677423 @default.
• W4281296355 cites W4281700140 @default.
• W4281296355 cites W4281988270 @default.
• W4281296355 cites W4282942298 @default.
• W4281296355 doi "https://doi.org/10.1101/2022.05.19.22275291" @default.
• W4281296355 hasPublicationYear "2022" @default.
• W4281296355 type Work @default.
• W4281296355 citedByCount "14" @default.
• W4281296355 countsByYear W42812963552022 @default.
• W4281296355 countsByYear W42812963552023 @default.
• W4281296355 crossrefType "posted-content" @default.
• W4281296355 hasAuthorship W4281296355A5022209651 @default.
• W4281296355 hasAuthorship W4281296355A5039317388 @default.
• W4281296355 hasAuthorship W4281296355A5041610413 @default.
• W4281296355 hasAuthorship W4281296355A5045925648 @default.
• W4281296355 hasAuthorship W4281296355A5068660339 @default.
• W4281296355 hasAuthorship W4281296355A5074151633 @default.
• W4281296355 hasBestOaLocation W42812963551 @default.
• W4281296355 hasConcept C126322002 @default.
• W4281296355 hasConcept C142462285 @default.
• W4281296355 hasConcept C167135981 @default.
• W4281296355 hasConcept C17923572 @default.
• W4281296355 hasConcept C201903717 @default.
• W4281296355 hasConcept C203014093 @default.
• W4281296355 hasConcept C207103383 @default.
• W4281296355 hasConcept C23131810 @default.
• W4281296355 hasConcept C2522874641 @default.
• W4281296355 hasConcept C2776376669 @default.
• W4281296355 hasConcept C2779298103 @default.
• W4281296355 hasConcept C2993143319 @default.
• W4281296355 hasConcept C44249647 @default.
• W4281296355 hasConcept C50382708 @default.
• W4281296355 hasConcept C71924100 @default.
• W4281296355 hasConcept C72563966 @default.
• W4281296355 hasConceptScore W4281296355C126322002 @default.
• W4281296355 hasConceptScore W4281296355C142462285 @default.
• W4281296355 hasConceptScore W4281296355C167135981 @default.
• W4281296355 hasConceptScore W4281296355C17923572 @default.
• W4281296355 hasConceptScore W4281296355C201903717 @default.
• W4281296355 hasConceptScore W4281296355C203014093 @default.
• W4281296355 hasConceptScore W4281296355C207103383 @default.
• W4281296355 hasConceptScore W4281296355C23131810 @default.
• W4281296355 hasConceptScore W4281296355C2522874641 @default.
• W4281296355 hasConceptScore W4281296355C2776376669 @default.
• W4281296355 hasConceptScore W4281296355C2779298103 @default.
• W4281296355 hasConceptScore W4281296355C2993143319 @default.
• W4281296355 hasConceptScore W4281296355C44249647 @default.
• W4281296355 hasConceptScore W4281296355C50382708 @default.
• W4281296355 hasConceptScore W4281296355C71924100 @default.
• W4281296355 hasConceptScore W4281296355C72563966 @default.
• W4281296355 hasLocation W42812963551 @default.
• W4281296355 hasOpenAccess W4281296355 @default.
• W4281296355 hasPrimaryLocation W42812963551 @default.
• W4281296355 hasRelatedWork W2026094606 @default.
• W4281296355 hasRelatedWork W2158701418 @default.
• W4281296355 hasRelatedWork W2515906920 @default.
• W4281296355 hasRelatedWork W2980864243 @default.
• W4281296355 hasRelatedWork W3042628958 @default.
• W4281296355 hasRelatedWork W3110151069 @default.
• W4281296355 hasRelatedWork W4210827470 @default.

• next